Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by ScienceBuffon Dec 10, 2020 6:09pm
165 Views
Post# 32084940

otena and the treatment of Crohn's?

otena and the treatment of Crohn's?Long-time Antibe investor...interesting to hear Dan discuss other roles for their hydrogen sulfide releasing drug platform.  He's mentioned a couple times now about a potential gastrointestinal indication for their platform.  Found a recent article co-authored by J.L. Wallace discussing the impact of Thrombin and induction of PAR-1 on inflammation and damage to the gastrointestinal tract associated with Crohn's disease. 

https://pubmed.ncbi.nlm.nih.gov/33201214/

Sounds like a potential role for Otenaproxesul in treating and managing Crohn's since Naproxen supresses thrombin.  Pharma focusing on Crohn's Disease is roughly a $8 billon dollar market right now and expected to grow to about $12 billion by 2029.




<< Previous
Bullboard Posts
Next >>